Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 14-Aug 11:00 AM ET)
RenovoRx Raises 2026 Guidance as Commercial Adoption Accelerates, Revenue Jumps 61% Sequentially
Market Chameleon (Thu, 13-Aug 7:59 AM ET)
RenovoRx GAAP EPS of -$0.06 beats by $0.01
Seeking Alpha News (Wed, 12-Aug 4:39 PM ET)
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
Globe Newswire (Tue, 11-Aug 8:30 AM ET)
Globe Newswire (Thu, 6-Aug 8:30 AM ET)
Globe Newswire (Tue, 4-Aug 8:30 AM ET)
Globe Newswire (Wed, 29-Jul 8:30 AM ET)
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Globe Newswire (Thu, 4-Jun 8:30 AM ET)
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Renovorx trades on the NASDAQ stock market under the symbol RNXT.
As of August 14, 2026, RNXT stock price climbed to $1.40 with 965,639 million shares trading.
RNXT has a beta of 0.72, meaning it tends to be less sensitive to market movements. RNXT has a correlation of 0.01 to the broad based SPY ETF.
RNXT has a market cap of $63.14 million. This is considered a Micro Cap stock.
Last quarter Renovorx reported $909,000 in Revenue and -$.05 earnings per share. This beat revenue expectation by $200,000 and exceeded earnings estimates by $.03.
In the last 3 years, RNXT traded as high as $2.35 and as low as $.53.
The top ETF exchange traded funds that RNXT belongs to (by Net Assets): VTI, VXF.
RNXT has underperformed the market in the last year with a return of +12.9%, while SPY returned +21.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RNXT shares. However, RNXT has outperformed the market in the last 3 month and 2 week periods, returning +63.7% and +46.1%, while SPY returned +4.0% and +3.9%, respectively. This indicates RNXT has been having a stronger performance recently.
RNXT support price is $1.20 and resistance is $1.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNXT shares will trade within this expected range on the day.